Sara M. Tolaney, MD, MPH, physician, instructor in medicine, Harvard Medical School, medical oncologist, Dana-Farber Cancer Institute, discusses patient selection for platinum-based therapy in triple-negative breast cancer (TNBC).
Sara M. Tolaney, MD, MPH
Advertisement
Sara M. Tolaney, MD, MPH, is the chief of theDdivision of Breast Oncology at Dana-Farber Cancer Institute in Boston, Massachusetts.
Articles by Sara M. Tolaney, MD, MPH
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dr Cloughesy on Extended Follow-Up Data for Vorasidenib in IDH1/2 Mutant Glioma
2
Bispecific ADC Iza-Bren Extends Survival in Advanced TNBC
3
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
4
Gedatolisib Combinations Double PFS in PIK3CA-Mutant Breast Cancer
5